Recent Quotes
My Watchlist
Indicators
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

725.72 -31.88 (-4.21%)
Official Closing Price Updated: 7:00 PM EST, Jan 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,560,329
Open 747.83
Bid (Size) 728.05 (5)
Ask (Size) 728.45 (1)
Prev. Close 757.60
Today's Range 725.01 - 755.28
52wk Range 612.70 - 972.53
Shares Outstanding N/A
Dividend Yield 0.72%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt
Deal opportunities abound: KKR & Co.'s stake in Maya; DuPont's electronics business; Ingevity's North Charleston site; and S&W Seed Company. 
Via Benzinga
Topics Government
Exposures Political
How Is The Market Feeling About Eli Lilly?
Via Benzinga

Performance

YTD
-6.73%
-6.73%
1 Month
-5.10%
-5.10%
3 Month
-20.94%
-20.94%
6 Month
-15.36%
-15.36%
1 Year
+16.42%
+16.42%

More News

Read More
Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review
Via Investor's Business Daily
Topics Economy
Exposures Interest Rates
Eli Lilly's Options: A Look at What the Big Money is Thinking
Via Benzinga
Here's How Much $1000 Invested In Eli Lilly 15 Years Ago Would Be Worth Today
Via Benzinga
Has Eli Lilly Stock Peaked?
Via The Motley Fool
Novo Nordisk Stock Tumbles As Ozempic Faces US Pricing Scrutiny, Semaglutide Trial Underwhelms: Retail Gets Anxious
Via Stocktwits
Here's How Donald Trump Could Shake Up Health Care — And Biotech Stocks
Via Investor's Business Daily
Topics Government
Exposures Political
FDA Approves Expanded Use Of Eli Lilly's Ulcerative Colitis Drug For Crohn's Disease
Via Benzinga
Exposures Product Safety
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
Via The Motley Fool
Could Donald Trump Make Eli Lilly Stock a No-Brainer Buy in 2025?
Via The Motley Fool
Topics Government
Exposures Political
9 of the 10 Largest Companies in the World Are Making Big Moves Into AI. Here's Why Investors Should Pay Attention.
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
My 10 Top Stocks to Buy to Start the New Year Off Right
Via The Motley Fool
Eli Lilly Adjusts Outlook, CEO David Ricks Explains Revenue Shortfall
Via Benzinga
Eli Lilly: What's Left To Like? A Lot, Says One Analyst.
Via Investor's Business Daily
Eli Lilly Gets Wall Street Backing After Tuesday’s Turmoil, Stock Rises Premarket As Retail Stays Bullish
Via Stocktwits
Topics Earnings
Exposures Financial
Microsoft, Applied Digital, Rigetti Computing, Eli Lilly, Tesla: Why These 5 Stocks Are On Investors' Radars Today
Via Benzinga
US Stocks Edge Higher As Traders Eye Inflation Data And Earnings Season Kickoff
Via Talk Markets
Topics Economy Stocks / Equities
Exposures Interest Rates
Stocks Fail To Rise Despite Benign Producer Inflation, 30-Year Treasury Yields Hit 5%, Ely Lilly Tumbles: What's Driving Markets Tuesday?
Via Benzinga
Topics Economy
Exposures Interest Rates
Eli Lilly Stock Faces Worst Day In Nearly 4 Years On Q4 Weight-Loss Drug Sales Miss, But Retail Bullish On 2025 Projections
Via Stocktwits
Topics Earnings
Exposures Financial
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Dropped on Tuesday
Via The Motley Fool
Eli Lilly Tumbles On Lowered Guidance As Weight-Loss Drug Sales Slow
Via Investor's Business Daily
Eli Lilly Cuts Q4 Revenue Guidance, Expects Around $5.5 Billion Sales From Weight Loss/Diabetes Drugs, Stock Tanks
Via Benzinga
Eli Lilly: 4 Reasons Investors Shouldn’t Miss This Opportunity
Via MarketBeat
Got $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows.
Via The Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.